Bandaríkin - enska - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14)] . tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2), (5.3), (5.4)] . there are no available data with tolterodine tartrate extended-release capsules use in pregnant women to inform drug-associated risks. in animal reproduction studies, oral administration of tolterodine and its 5-hmt metabolite to pregnant mice during organogenesis did not produce adverse developmental outco

Bandaríkin - enska - NLM (National Library of Medicine)

mylan institutional inc. - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14)] . tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2), ( 5.3), ( 5.4)] . at approximately 9 to 12 times the clinical exposure to the pharmacolo

Bandaríkin - enska - NLM (National Library of Medicine)

greenstone llc - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ]. tolterodine tartrate extended- release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended- release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended- release capsules , are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2) (5.3) , (5.4) ]. risk summary there are no available data with tolterodine tartrate extended- release capsules use in pregnant women to inform drug-associated risks. in animal reproduction studies, oral administration of tolterodine and its 5-hmt metabolite to pregnant mice during organogenesis did not produce adverse

Bandaríkin - enska - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14)]. tolterodine  tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which , like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions  (5.2)(5.3), (5.4) ]. pregnancy category c. at approximately 9 to 12 times the clinical exposure to the pharmacologically active components of tolterodine tartrate extended-release capsules, no anomalies or malformations were observed in mice (based on the auc of tolterodine and its 5-hmt metabolite at a dose of 20 mg/kg/d

Bandaríkin - enska - NLM (National Library of Medicine)

athem llc - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. tolterodine tartrate tablets are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate is also contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate, are metabolized to 5-hydroxymethyl tolterodine.

Bandaríkin - enska - NLM (National Library of Medicine)

carilion materials management - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 4 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ] . tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsulesare also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2) (5.3), (5.4) ]. pregnancy category c. at approximately 9–12 times the clinical exposure to the pharmacologically active components of tolterodine tartrate extended-release capsules, no anomalies or malformations were observed in mice (based on the auc of tolterodine and its 5-hmt metabolite at a dose of 20 mg/kg/day). at

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - tolterodine tartrate 1mg equivalent to tolterodine 0.68 mg - film coated tablet - 1 mg - active: tolterodine tartrate 1mg equivalent to tolterodine 0.68 mg excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry white 03f58763 purified water   sodium starch glycolate - arrow – tolterodine 1 & arrow tolterodine 2 are indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - tolterodine tartrate 2mg equivalent to tolterodine 1.37 mg - film coated tablet - 2 mg - active: tolterodine tartrate 2mg equivalent to tolterodine 1.37 mg excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry white 03f58763 purified water   sodium starch glycolate - arrow – tolterodine 1 & arrow tolterodine 2 are indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - tolterodine l-tartrate 4 mg - eq. tolterodine 2,74 mg - prolonged-release capsule, hard - 4 mg - tolterodine tartrate 4 mg - tolterodine

Bandaríkin - enska - NLM (National Library of Medicine)

carilion materials management - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. tolterodine tablets are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tablets are also contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tablets, are metabolized to 5-hydroxymethyl tolterodine.